Atlas Trials

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Clinical trial NCT01682616 · COMPLETED

Trial details

NCT number
NCT01682616
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Small Lymphocytic LymphomaChronic Lymphocytic Leukemia
Start date
2012-07-25
Primary completion
2022-06-23
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.